China Diagnostic Reagent Company Goes Global
This article was originally published in PharmAsia News
Shanghai Kehua Bio-engineering Co., Ltd., a major diagnostic reagent manufacturer in China, announced that its 42 diagnostic reagents and three medical devices have received the CE marking, which means it can enter the EU market. The company will be setting up a joint venture with leading diagnostic equipment manufacturer Bio Merieux. The worldwide diagnostic reagent business is worth $20 billion, and the 4-billion-yuan China market is expected to grow at 15-20 percent annually over the next five years. The business potential is attracting MNCs, which will intensify the competition for local players greatly limited by size, product varieties and poor development. (Click here for more - Chinese Language)
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.